Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer
Background: This analysis was done with the aim to study the overall impact of docetaxel and cabazitaxel treatment using quality-adjusted time without symptoms and toxicity (QTWiST) analysis in head and neck cancer patients receiving second-line treatment. Methods: Overall survival (OS) was partitio...
Main Authors: | Vijay Patil, Amit Joshi, Vanita Noronha, Sachin Dhumal, Arun Chandrasekharan, Nikhil Pande, Sameer Shrirangwar, Anup Toshniwal, Siddharth Turkar, Kushal Gupta, Vikas Talreja, Abhishek Mahajan, Shashikant Juvekar, Atanu Bhattacharjee, Kumar Prabhash |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Cancer Research, Statistics, and Treatment |
Subjects: | |
Online Access: | http://www.crstonline.com/article.asp?issn=2590-3233;year=2018;volume=1;issue=1;spage=46;epage=50;aulast= |
Similar Items
-
TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
by: Yohei Sekino, et al.
Published: (2019-08-01) -
Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
by: Peng-Fei Zhang, et al.
Published: (2021-01-01) -
Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety
by: M. I. Volkova, et al.
Published: (2019-06-01) -
Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients
by: Vijay Patil, et al.
Published: (2018-01-01) -
Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)